Bioferon (interferon alpha 2b)
/ Biosidus
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
December 26, 2017
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1378 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)
New P3 trial • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4
December 15, 2023
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1345 | Active, not recruiting | Sponsor: National Cancer Institute (NCI)
Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4
March 13, 2025
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1301 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026
Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4
March 04, 2026
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1301 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027
Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4
December 29, 2017
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1378 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Jun 2020 ➔ Sep 2023
Trial primary completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • CD4
November 06, 2015
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1378 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting
Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4
August 21, 2017
SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
(clinicaltrials.gov)
- P3 | N=1378 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting
Enrollment closed • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • CD4
March 05, 2026
SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
(clinicaltrials.gov)
- P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027
Trial completion date • Endocrine Cancer • Gastric Cancer • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma
June 27, 2025
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Active, not recruiting ➔ Terminated; Funding ended
Trial completion date • Trial termination • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
April 28, 2025
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=5 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=15 ➔ 5 | Trial completion date: Jun 2025 ➔ Dec 2025
Enrollment change • Enrollment closed • Trial completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
May 30, 2024
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2025
Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
February 01, 2024
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
October 31, 2023
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jun 2025 ➔ Dec 2025 | Initiation date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2025 ➔ Dec 2025
Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
July 21, 2023
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jul 2027 ➔ Jun 2025 | Trial primary completion date: Jul 2026 ➔ Jun 2025
Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
May 31, 2023
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Apr 2027 ➔ Jul 2027 | Trial primary completion date: Apr 2026 ➔ Jul 2026
Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
March 06, 2023
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute
Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
1 to 16
Of
16
Go to page
1